These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32775300)

  • 1. PD-L1 Under Regulation of miR-429 Influences the Sensitivity of Gastric Cancer Cells to TRAIL by Binding of EGFR.
    Lv J; Guo T; Qu X; Che X; Li C; Wang S; Gong J; Wu P; Liu Y; Liu Y; Xu L
    Front Oncol; 2020; 10():1067. PubMed ID: 32775300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
    Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
    J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRAIL-activated EGFR by Cbl-b-regulated EGFR redistribution in lipid rafts antagonises TRAIL-induced apoptosis in gastric cancer cells.
    Xu L; Zhang Y; Liu J; Qu J; Hu X; Zhang F; Zheng H; Qu X; Liu Y
    Eur J Cancer; 2012 Nov; 48(17):3288-99. PubMed ID: 22456178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction.
    Hendriks D; He Y; Koopmans I; Wiersma VR; van Ginkel RJ; Samplonius DF; Helfrich W; Bremer E
    Oncoimmunology; 2016 Aug; 5(8):e1202390. PubMed ID: 27622071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Src/caveolin-1-regulated EGFR activation antagonizes TRAIL-induced apoptosis in gastric cancer cells.
    Xu L; Qu X; Li H; Li C; Liu J; Zheng H; Liu Y
    Oncol Rep; 2014 Jul; 32(1):318-24. PubMed ID: 24840271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular mechanism of cisplatin to enhance the ability of TRAIL in reversing multidrug resistance in gastric cancer cells].
    Zhu X; Zhang K; Wang Q; Chen S; Gou Y; Cui Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):404-11. PubMed ID: 26463141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-21 Participates in the PD-1/PD-L1 Pathway-Mediated Imbalance of Th17/Treg Cells in Patients After Gastric Cancer Resection.
    Zheng X; Dong L; Wang K; Zou H; Zhao S; Wang Y; Wang G
    Ann Surg Oncol; 2019 Mar; 26(3):884-893. PubMed ID: 30565043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of AAV-TRAIL with miR-221-Zip Therapeutic Strategy Overcomes the Resistance to TRAIL Induced Apoptosis in Liver Cancer.
    Ma S; Sun J; Guo Y; Zhang P; Liu Y; Zheng D; Shi J
    Theranostics; 2017; 7(13):3228-3242. PubMed ID: 28900506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR3609 sensitizes breast cancer cells to adriamycin by blocking the programmed death-ligand 1 immune checkpoint.
    Li D; Wang X; Yang M; Kan Q; Duan Z
    Exp Cell Res; 2019 Jul; 380(1):20-28. PubMed ID: 30904483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab enhances TRAIL-induced gastric cancer cell apoptosis by promoting DISC formation in lipid rafts.
    Xu L; Hu X; Qu X; Hou K; Zheng H; Liu Y
    Biochem Biophys Res Commun; 2013 Sep; 439(2):285-90. PubMed ID: 23973713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer.
    Zhang N; Zeng Y; Du W; Zhu J; Shen D; Liu Z; Huang JA
    Int J Oncol; 2016 Oct; 49(4):1360-8. PubMed ID: 27499357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-200c Nanoparticles Sensitized Gastric Cancer Cells to Radiotherapy by Regulating PD-L1 Expression and EMT.
    Qian L; Liu F; Chu Y; Zhai Q; Wei X; Shao J; Li R; Xu Q; Yu L; Liu B; Liu Q
    Cancer Manag Res; 2020; 12():12215-12223. PubMed ID: 33273858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-138 enhances TRAIL-induced apoptosis through interferon-stimulated gene 15 downregulation in hepatocellular carcinoma cells.
    Zuo C; Sheng X; Liu Z; Ma M; Xiong S; Deng H; Li S; Yang D; Wang X; Xiao H; Quan H; Xia M
    Tumour Biol; 2017 Jun; 39(6):1010428317710410. PubMed ID: 28639887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.
    Suda K; Rozeboom L; Rivard CJ; Yu H; Ellison K; Melnick MAC; Hinz TK; Chan D; Heasley LE; Politi K; Mitsudomi T; Hirsch FR
    Lung Cancer; 2017 Jul; 109():1-8. PubMed ID: 28577937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 Inhibitor Regulates the miR-33a-5p/PTEN Signaling Pathway and Can Be Targeted to Sensitize Glioblastomas to Radiation.
    Xia W; Zhu J; Tang Y; Wang X; Wei X; Zheng X; Hou M; Li S
    Front Oncol; 2020; 10():821. PubMed ID: 32537433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-494 Sensitizes Gastric Cancer Cells to TRAIL Treatment Through Downregulation of Survivin.
    Xu S; Li D; Li T; Qiao L; Li K; Guo L; Liu Y
    Cell Physiol Biochem; 2018; 51(5):2212-2223. PubMed ID: 30537730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells.
    Zuo Y; Zheng W; Liu J; Tang Q; Wang SS; Yang XS
    Neoplasma; 2020 Jan; 67(1):93-101. PubMed ID: 31777260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
    Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
    Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of anti-PD-L1 monoclonal antibody and EGFR-TKI on the expression of PD-L1 and function of T lymphocytes in EGFR-mutated lung cancer cells].
    She Y; Pan X; Xing YF; Zhou T; Zhang ZL; Shi MH; Chen YJ
    Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):886-892. PubMed ID: 27998463
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.